Small molecule therapies with expansive potential

Platinum-Resistant Ovarian Cancer (PROC) - Redefining the Horizon for Ovarian Cancer

While initial platinum-based treatment for ovarian cancer often yields strong response, 60-70%¹ of patients will eventually develop resistance. For patients facing platinum-resistant ovarian cancer (PROC), the treatment landscape has historically been limited to single-agent chemotherapies with low response rates and cumulative toxicities. Further, while next-generation antibody-drug conjugates (ADCs) may target tumor cells more selectively, most patients will still rapidly develop resistance, leaving significant unmet medical need for non-chemotherapy and non-antibody-based therapeutic options. At Accent, we recognize that these patients cannot wait for incremental progress. We are driven by the urgent need to advance ATX-295, our potentially best-in-class KIF18A inhibitor, for PROC patients and to provide a clinically meaningful and oral treatment option.

Squamous Non-Small Cell Lung Cancer (sqNSCLC) - Closing the Gap in Precision Oncology

Squamous cell carcinoma represents a significant portion - 20% to 30%² - of all lung cancer diagnoses, yet it has remained largely in the shadow of the genomically-driven cancer precision medicine revolution we have witnessed in non-squamous NSCLC. Unlike other lung cancer subtypes, sqNSCLC lacks common actionable mutations, leaving patients heavily reliant on traditional chemotherapy and immunotherapies. When these standard options are exhausted, the therapeutic void is profound - current SOC is docetaxel with a response rate <10% and PFS <3 mo. We are committed to changing this narrative by targeting the unique high-CIN biology of sqNSCLC with ATX-295, aiming to provide meaningful benefits and improved quality of life for a patient population that has been historically underserved.

Following the Biology to Expand Patient Impact

Because KIF18A inhibition targets a fundamental, shared biological vulnerability across multiple cancer types (e.g., breast, endometrial, head-and-neck), its potential reaches far beyond our initial clinical focus. We are actively researching and evaluating how we can help patients with high unmet medical need whose cancers share these same underlying biological signatures.

We are also rigorously exploring how ATX-295 can combine with both established standard of care and novel therapeutic agents. By combining with other mechanistically-aligned treatments, ATX-295 has the potential to deepen patient response and durability of treatment even further than either therapeutic alone.